

11:05	S4	Brief Overview of AIDS Malignancies and Patient Care in India Kapila Bharucha, M.D., B.J. Medical College India
11:30	S5	Viral Lymphoproliferative Diseases in Brazil William Harrington, Jr., M.D., University of Miami
	S6	AIDS Related Malignancies in Brazil Carlos Brites, M.D., Federal University of Bahia, Brazil
11:55	S7	Considerations for International Collaboration in East Africa: Case Western Reserve University (CWRU) Experience Scot Remick, M.D., CWRU
Noon	S8	Brief Overview of AIDS Malignancies and Patient Care in Uganda Edward Katongole-Mbidde, M.B., Ch.B., Uganda Cancer Institute, Uganda
12:10	S9	Brief Overview of AIDS Malignancies and Patient Care in Kenya Walter Mwanda Otieno, M.B., Ch.B., University of Nairobi College of Health Sciences, Kenya
12:20		Panel Discussion
12:30 PM		Lunch (on your own)
1:30-2:15 PM		ABSTRACT PRESENTATIONS Moderator: Michael Marco, Treatment Action Group Robert Yarchoan, M.D., National Cancer Institute
1:30	4	HIV-1 Related Kaposi's Sarcoma (KS) in the HAART Era. Non- nucleoside Reverse Transcriptase Inhibitors Are as Effective at Preventing KS as Protease Inhibitors Mark Bower Ph.D., F.R.C.P., Chelsea and Westminster Hospital, United Kingdom
1:45	5	Angiogenesis Inhibitor IM862 is Ineffective Against AIDS-KS in a Randomized, Placebo Controlled Trial Ariela Noy, M.D., Memorial Sloan-Kettering Cancer Center
2:00	6	Preliminary Results of Combination Liposomal Doxorubicin and Interleukin-12 Followed by Chronic IL-12 Maintenance Therapy in Advanced AIDS-related KS Richard Little, M.D., National Cancer Institute
2:15-4:10 PM		PLENARY LECTURES Moderators: Alexandra Levine, M.D., Keck School of Medicine, University of Southern California Robert Yarchoan, M.D., National Cancer Institute
2:15	S10	National Institutes of Health: Inter-Institute Pilot Program For AIDS Drug Discovery and Development Edward Sausville, M.D., National Cancer Institute
2:40		Break
2:55	S11	Molecularly Targeted Approaches in KS Treatment S. Gail Eckhardt, M.D., University of Colorado
3:20	S12	Experimental Immune-based Approaches in the Treatment of Lymphomas Michael Caligiuri, M.D., The Ohio State University

- 3:45 S13 Development of Novel Epstein-Barr Virus (EBV)-targeted Treatments for AIDS-associated Lymphoproliferative Disease
Shannon Kenney, M.D., University of North Carolina at Chapel Hill
- 4:10-4:55 PM **ABSTRACT PRESENTATIONS**
Moderators: Alexandra Levine, M.D., Keck School of Medicine, University of Southern California
Michael Marco, Treatment Action Group
- 4:10 7 Humanized Anti-CD20 Monoclonal Antibody for the Treatment of Lymphoproliferative Disease Developing in Pediatric Solid Organ Transplant Recipients
Barbara Savoldo, M.D., Baylor College of Medicine
- 4:25 8 Front Line Therapy for AIDS-related Lymphoma With Liposomal Doxorubicin (D-99, Myocet), Cyclophosphamide, Vincristine and Prednisone
Anil Tulpule, M.D., Keck School of Medicine, University of Southern California
- 4:40 9 Infusional Cyclophosphamide, Doxorubicin and Etoposide in HIV-associated Lymphoma: Long-term Followup in ECOG Trial E1494
Joseph Sparano, M.D., Montefiore Medical Center
- 4:55-5:25 PM Authors at Posters
- 4:55-6:00 PM **RECEPTION**
Atrium on First Floor Concourse

TUESDAY, APRIL 23

- 8:00 AM-6:00 PM **POSTER PRESENTATIONS**
Atrium on First Floor Concourse and Conference Room E on Lower Level (Abstracts 32-89)
- 8:30-10:00 AM **PLENARY LECTURES - Virus Replication and Immune Responses to Infection**
Moderators: Patrick Moore, M.D., Hillman Cancer Center and University of Pittsburgh
Paul Lambert, M.D., University of Wisconsin Medical School
- 8:30 S14 HPV Replication in Epithelial Cells
Laimonis 'Lou' Laimins, Ph.D., Northwestern University
- 9:00 S15 EBV Glycoproteins and Their Interaction With Receptors
Lindsey Hutt-Fletcher, Ph.D., University of Missouri-Kansas City
- 9:30 S16 Kaposi's Sarcoma Herpesvirus (KSHV) Receptors
Bala Chandran, Ph.D., University of Kansas
- 10:00 AM Break
- 10:15 AM-12:15 PM **ABSTRACT PRESENTATIONS**
- 10:15 10 The Virion-associated Glycoprotein B of KSHV and Its Macaque Homolog, Retroperitoneal Fibromatosis Herpesvirus Contain a Conserved RGD Domain Which Mediates Binding to a Cellular Integrin Receptor
Timothy Rose, Ph.D., University of Washington

- 10:30 11 Identification and Characterization of a Polycistronic Transcript of Rhesus Monkey Rhadinovirus (RRV) Encoding for the RRV Orf 50/Rta Transactivator and the RRV R8 and R8.1 Genes
Blossom Damania, Ph.D., University of North Carolina-Chapel Hill
- 10:45 12 Early Events in KSHV Infection of Primary Endothelial Cells
Bruce J. Dezube, M.D., Beth Israel Deaconess Medical Center
- 11:00 13 Identification of the KSHV Lytic Origin of DNA Replication
Yan Yuan, Ph.D., University of Pennsylvania
- 11:15 14 The KSHV Lytic Replication-associated Protein Causes p21-mediated G1 Cell Cycle Arrest During Viral Lytic Replication Through the Induction of CCAAT/Enhance-binding Protein Alpha
Frederick Wu, A.B.D., Johns Hopkins School of Medicine
- 11:30 15 The Epstein-Barr SM Protein Activates STAT1 and Induces Interferon Stimulated Gene Expression by an Interferon-independent Mechanism
Sankar Swaminathan, M.D., University of Florida Shands Cancer Center
- 11:45 16 Histone Deacetylase Inhibitors Reactivate KSHV
Nickolai Talanin, M.D, Ph.D., National Cancer Institute
- Noon 17 KSHV ORF 34 Promoter Encodes a Functional Hypoxia Response Element That Is Induced by HIF-2 Alpha
Muzammel Haque, Ph.D, National Cancer Institute
- 12:15 PM Lunch (on your own)
- 1:15-3:30 PM **PLENARY LECTURES - Virus Transformation and Oncogenesis**
Moderators: Joseph Pagano, M.D., University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center
Thomas Schulz, M.D., Hannover Medical School, Germany
- 1:15 S17 Functions of the HPV E6 Protein
Elliot Androphy, M.D., University of Massachusetts Medical School
- 1:45 S18 EBERs and Their Effects in Latent EBV Infection
Jeffrey Sample, Ph.D., St. Jude Children's Hospital
- 2:15 S19 Expression of KSHV in Human Malignancies
Patrick Moore, M.D., Columbia University
- 2:45 Break
- 3:00 S20 B Cell Development and Oncogenesis
Ralf Küppers, Ph.D., University of Cologne, Germany
- 3:30-5:00 PM **ABSTRACT PRESENTATIONS**
- 3:30 18 KSHV and HIV-1 Infections in a Cohort of Mother/Infant Pairs in Zambia
Charles Wood, M.D., University of Nebraska-Lincoln
- 3:45 19 KSHV Latency Associated Nuclear Antigen (LANA) Immortalizes Primary Human Umbilical Vein Endothelial Cells
Andrew Blauvelt, M.D., National Cancer Institute

- 4:00 20 KSHV-induced Upregulation of the C-kit Proto-oncogene as Identified by Gene Expression Profiling Induces Endothelial Cell Transformation
Klaus Früh, Ph.D., Oregon Health and Science University
- 4:15 21 The Role of EBV Nuclear Protein 3A in Lymphocyte Transformation
Seiji Maruo, M.D., Ph.D., Brigham and Women's Hospital
- 4:30 22 Activation of the P13-Kinase AKT Pathway by EBV Latent Membrane Protein 2A
Jennifer Harrelson, B.S., University of North Carolina-Chapel Hill and Lineberger Comprehensive Cancer Center
- 4:45 23 Constitutively Activated STAT3 Induces Survivin Expression and Prevents Apoptosis in Primary Effusion Lymphoma Cells
Yoshiyasu Aoki, M.D., Ph.D., National Cancer Institute
- 5:00-5:30 PM **Authors at Posters**
- 5:00-6:00 PM **RECEPTION**
Atrium on First Floor Concourse

WEDNESDAY, APRIL 24

- 8:00 – 11:45 AM **POSTER PRESENTATIONS**
Atrium on First Floor Concourse and Conference Room E on Lower Level (Abstracts 32-90)
- 8:30-10:00 AM **PLENARY LECTURES - Virus Latency, Persistence, and Immune Responses**
Moderators: Kenneth Cremer, Ph.D., National Cancer Institute
Elliott Kieff, M.D., Ph.D., Channing Laboratories, Brigham and Women's Hospital, and Harvard University
- 8:30 S21 HPV VLP Vaccines and Prevention of HPV 16 Infection and Oncogenesis
Laura Koutsky, Ph.D., University of Washington
- 9:00 S22 EBNA-1 and Initiation of Episome DNA Synthesis
John Yates, Ph.D., Roswell Park Cancer Institute
- 9:30 S23 A KSHV-encoded Interferon Regulatory Factor Expressed in Latency
Frank Neipel, M.D., University of Erlangen, Germany
- 10:00 - Noon **ABSTRACT PRESENTATIONS**
- 10:00 24 Lymphoproliferative Cellular Immune Response to HPV 16 E6 and E7 Peptides in HIV Infected Women Are Independent of CD4 Counts, but Are Associated With Clearance of HPV Infection
Anna Kadish, M.D., Albert Einstein College of Medicine
- 10:15 25 Detection of KSHV in the Saliva of Immunocompetent and Immunosuppressed Individuals
Jennifer Webster-Cyriaque, D.D.S., Ph.D., University of North Carolina at Chapel Hill
- 10:30 26 Defective OCT Transcription Factor Expression/Activity May Explain Impaired Immunoglobulin Expression in KSHV-Infected Primary Effusion Lymphoma Cells
Daniel DiBartolo, B.A., Cornell University - Weill Medical College

10:45	28	Telomeric Proteins Regulate Plasmid Maintenance of EBV Paul Lieberman, Ph.D., Wistar Institute
11:00	29	The KSHV LANA Is Targeted to Chromosomes by Two Chromosome Associated Proteins Through Both LANA N- and C-terminal Interactions Anita Krithivas, B.S., Johns Hopkins University School of Medicine
11:15	30	Tumorigenesis After Experimental Infection in an EBV Animal Model Fred Wang, M.D., Harvard Medical School
11:30	31	EBV and Breast Cancer: Association Without Causality? Jian Huang, M.S.E., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
11:45		End of Conference

CME

The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) designates this educational activity for a maximum of 17.5 hrs in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. To obtain certification of attendance, please obtain a CME form from the registration desk outside the main auditorium.